ArticleAnnals of surgical oncology2026
Prognostic Significance of the T12-SMI Before and After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesThis study evaluated the prognostic value of the 12th thoracic vertebra skeletal muscle mass index (T12-SMI) before and after neoadjuvant chemoimmunotherapy (NACI) in patients with esophageal squamous cell carcinoma (ESCC).
methodsWe retrospectively analyzed 211 patients with ESCC who underwent NACI followed by esophagectomy between 2020 and 2022. According to their SMI at T12, the patients were divided into a muscle attenuation group (MAG) and a normal group (NG) before or after NACI. The perioperative outcomes and survival data were compared between the two groups.
resultsThe pathological complete response (pCR) rates and major pathological response rates were comparable between the MAG and NG before and after NACI (all P > 0.05). The postoperative complication rates and 90-day mortality rates were also comparable (all P > 0.05). However, compared with the NG, the MAG had significantly worse overall survival and disease-free survival, both before and after NACI (all P < 0.05). Multivariate analyses confirmed that muscle attenuation post-NACI was an independent prognostic factor for overall survival (hazard ratio 2.977; 95% confidence interval 1.733-5.113; P < 0.001) and disease-free survival (hazard ratio 2.355; 95% confidence interval 1.339-4.142; P = 0.003). Post-NACI, the MAG had higher overall recurrence rates (41.7% vs. 21.1%, P = 0.009), particularly for distant metastases (22.2% vs. 9.1%, P = 0.024).
conclusionSarcopenia at the T12 level after NACI is an independent predictor of poor survival for patients with ESCC and is associated with increased postoperative recurrence risk, especially for distant metastases.
Indexed as
Identifiers
42251209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.